Month: November 2022

Bankar, Aniket; Lipton, Jeffrey H. published an article in 2022, the title of the article was Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.SDS of cas: 380843-75-4 And the article contains the following content:

Implications of creatine kinase (CK) elevation, a frequent complication of tyrosine kinase inhibitor (TKI) treatment for chronic myeloid leukemia (CML), on its key treatment outcomes (overall survival (OS) and event-free survival (EFS)), remain unknown. In this single center, retrospective study on 283 chronic phase CML patients on first-line TKI (median follow-up of 8.8 years), 71.7% patients had hyperCKemia with no difference in incidence between imatinib and second generation TKIs (SG-TKIs). In multivariable Cox regression anal., hyperCKemia was associated with better OS and intermediate- and high-Sokal risk score with worse OS. In multivariable Cox regression for EFS, hyperCKemia and treatment with SG-TKI were associated with improved EFS while intermediate or high Sokal index and higher comorbidities showed worse EFS. Our study provides an evidence on the prognostic value of hyperCKemia in CML and informs clinicians not to change TKI based solely on laboratory elevations of CK. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to creatine kinase chronic myeloid leukemia, chronic myeloid leukemia, creatine kinase, tyrosine kinase inhibitors, Mammalian Pathological Biochemistry: Oncology and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Huang, Jing; Huo, Hongqi; Lu, Rong published an article in 2022, the title of the article was A novel signature of necroptosis-associated genes as a potential prognostic tool for head and neck squamous cell carcinoma.Electric Literature of 380843-75-4 And the article contains the following content:

Head and neck squamous cell carcinoma (HNSCC) arises from squamous cells in the oral cavity, pharynx and larynx. Although HNSCC is sensitive to radiotherapy, patient prognosis is poor. Necroptosis is a novel programmed form of necrotic cell death. The prognostic value of necroptosis-associated gene expression in HNSCC has not been explored. We downloaded mRNA expression data of HNSCC patients from TCGA databases and Gene Expression Omnibus (GEO) databases, and compared gene expression between tumor tissues and adjacent normal tissues to identify differentially expressed genes (DEGs) and necroptosis-related prognostic genes. A model with necroptosis-related genes was established to predict patient prognosis via LASSO method and Kaplan-Meier anal. GSE65858 data set (n = 270) from GEO was used to verify the model’s predictive ability. Gene set enrichment analyses, immune microenvironment anal., principal component anal., and anti-tumor compound IC50 prediction were also performed. We identified 49 DEGs and found 10 DEGs were associated with patient survival (p < 0.05). A risk model of 6-gene signature was constructed using the TCGA training data set and further validated with the GEO data set. Patients in the low-risk group survived longer than those in the high-risk group (p < 0.05) in the GEO validation sets. Functional anal. showed the two patient groups were associated with distinct immunity conditions and IC50. We constructed a prognostic model with 6 necroptosis-associated genes for HNSCC. The model has potential usage to guide treatment because survival was different between the two groups. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Electric Literature of 380843-75-4

The Article related to head and neck squamous cell carcinoma necroptosis prognosis, immune, necroptosis, prognosis, risk score, squamous cell carcinoma, tumor, Mammalian Pathological Biochemistry: Oncology and other aspects.Electric Literature of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 15, 2021, Deng, Yanlin; Liu, Sylvia Yang; Chua, Song Lin; Khoo, Bee Luan published an article.Computed Properties of 86393-32-0 The title of the article was The effects of biofilms on tumor progression in a 3D cancer-biofilm microfluidic model. And the article contained the following:

Components within the tumor microenvironment, such as intratumoral bacteria (IB; within tumors), affect tumor progression. However, current exptl. models have not explored the effects of extratumoral bacteria (EB; outside tumors) on cancer progression. Here, we developed a microfluidic platform to analyze the influence of bacterial distribution on bladder cancer progression under defined conditions, using uropathogenic Escherichia coli. This was achieved by establishing coating (CT) and colonizing (CL) models to simulate the different invasion and colonization modes of IB and EB in tumor tissues. We demonstrated that both EB and IB induced closer cell-cell contacts within the tumor cluster, but cancer cell viability was reduced only in the presence of IB. Interestingly, cancer stem cell counts increased significantly in the presence of EB. These outcomes were due to the formation of extracellular DNA-based biofilms by EB. Triple therapy of DNase (anti-biofilm agent), ciprofloxacin (antibiotic), and doxorubicin (anti-cancer drug) could effectively eradicate biofilms and tumors simultaneously. Our preclin. proof-of-concept provides insights on how bacteria can influence tumor progression and facilitate future research on anti-biofilm cancer management therapies. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to cancer progression biofilm microfluidic model, antibacterial agents, biofilms, combinatorial therapy, drug screening, microfluidic tumor models, Mammalian Pathological Biochemistry: Oncology and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 1, 2022, Campbell, Marcia R.; Ruiz-Saenz, Ana; Peterson, Elliott; Agnew, Christopher; Ayaz, Pelin; Garfinkle, Sam; Littlefield, Peter; Steri, Veronica; Oeffinger, Julie; Sampang, Maryjo; Shan, Yibing; Shaw, David E.; Jura, Natalia; Moasser, Mark M. published an article.SDS of cas: 380843-75-4 The title of the article was Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. And the article contained the following:

Effective inactivation of the HER2-HER3 tumor driver has remained elusive because of the challenging attributes of the pseudokinase HER3. We report a structure-function study of constitutive HER2-HER3 signaling to identify opportunities for targeting. The allosteric activation of the HER2 kinase domain (KD) by the HER3 KD is required for tumorigenic signaling and can potentially be targeted by allosteric inhibitors. ATP binding within the catalytically inactive HER3 KD provides structural rigidity that is important for signaling, but this is mimicked, not opposed, by small mol. ATP analogs, reported here in a bosutinib-bound crystal structure. Mutational disruption of ATP binding and mol. dynamics simulation of the apo KD of HER3 identify a conformational coupling of the ATP pocket with a hydrophobic AP-2 pocket, analogus to EGFR, that is critical for tumorigenic signaling and feasible for targeting. The value of these potential target sites is confirmed in tumor growth assays using gene replacement techniques. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to amplified cancer epidermal growth factor receptor tumorigenic signaling, ap-2 pocket, erbb2, erbb3, her2, her3, allosteric inhibitor, bosutinib, breast cancer, Mammalian Pathological Biochemistry: Oncology and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Iriyama, Noriyoshi; Miura, Katsuhiro; Uchino, Yoshihito; Takahashi, Hiromichi; Nakagawa, Masaru; Iizuka, Kazuhide; Hamada, Takashi; Koike, Takashi; Kurihara, Kazuya; Nakayama, Tomohiro; Takei, Masami; Hatta, Yoshihiro; Nakamura, Hideki published an article in 2022, the title of the article was Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.HPLC of Formula: 380843-75-4 And the article contains the following content:

Some chemotherapeutic agents cause carnitine deficiency, which causes general fatigue. However, there is no study on carnitine deficiency in patients with chronic myeloid leukemia (CML) during tyrosine kinase inhibitor (TKI) therapy. In this study, we investigated carnitine concentrations in patients with CML receiving TKI therapy. This study included patients with well-controlled CML. Total carnitine and free carnitine concentrations were evaluated using the enzyme cycling method. The brief fatigue inventory (BFI) and cancer fatigue scale (CFS) were used to assess general fatigue developed during TKI therapy. Fifty-five patients on TKI therapy were included. Of these, 12 (21.8%) patients had low free carnitine concentrations Free carnitine concentrations were higher in men than in women. Younger age was closely associated with lower free carnitine concentrations TKI type, TKI dose, treatment response, or therapy duration were not associated with free carnitine concentrations None of the scores (the global fatigue score with the BFI and CFS score) correlated with carnitine concentrations Concentrations of free carnitine in patients in the treatment-free remission group were slightly higher than those in the TKI group, with only 9.1% having a low concentration of free carnitine. Carnitine deficiency is probably not a major cause of general fatigue but may occur in patients with CML receiving TKI therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).HPLC of Formula: 380843-75-4

The Article related to carnitine tyrosine kinase inhibitor anticancer chronic myeloid leukemia, carnitine deficiency, chronic myeloid leukemia, general fatigue, tyrosine kinase inhibitor, Mammalian Pathological Biochemistry: Oncology and other aspects.HPLC of Formula: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 1997, Schierholz, Joerg M.; Rump, Alexis; Pulverer, Gerhard published an article.Computed Properties of 86393-32-0 The title of the article was New antiinfectious biomaterials. Ciprofloxacin containing polyurethanes as potential drug delivery systems to prevent foreign-body infections. And the article contained the following:

Device related infections are an increasing problem since foreign materials are used in modern medicine. Ciprofloxacin-HCl salt (CAS 86393-32-0) and lipophilic ciprofloxacin-betaine (Bay o 9867) incorporated into polyurethanes by solvent casting technique were studied in order to develop antiinfectious properties of this biomaterial. Drug release rates, bacterial colonization and morphol. features of the polymer-ciprofloxacin combinations were studied and the physico-chem. mechanisms of the delivery were discussed. Ciprofloxacin salt showed a fast initial release rate, whereas ciprofloxacin-betaine was characterized by a more continuous release behavior. A higher diffusion of the lipophilic ciprofloxacin-betaine in the polymer could be shown as compared to its salt incorporated into the polyurethane. Bacterial colonization to the antibiotic-loaded polyurethanes was inhibited effectively only by preparations showing a slower but more sustained drug release. SEM demonstrated that the polyurethane-antibiotic combination was most homogeneous for ciprofloxacin-betaine. Polyurethane material loaded with ciprofloxacin salt showed crystals at the surface and a granular structure of the polymeric matrix. Crystalline structure of the drug on polymeric surfaces varied with loading concentration and lipophilicity. High homogeneity is required for a sustained and prolonged release and effective inhibition of bacterial colonization. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to ciprofloxacin release polyurethane prosthetic, biomaterial polyurethane infection inhibition, Pharmaceuticals: Prosthetics and Medical Goods and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 30, 1996, Linnhoff, G. Caldero; Vidal, R. Canals; Ges, J. M. Caldero published an article.Product Details of 86393-32-0 The title of the article was Spectrophotometric study of ciprofloxacin solutions in the presence of ferric ions in acid medium. And the article contained the following:

Spectrophotometric anal. of ciprofloxacin solutions depending on the pH has allowed the acidity constant Ka = (2.80 ± 0.2) × 10-7 (pKa = 6.55 ± 0.05) to be determined Spectrophotometric studies of ciprofloxacin solutions in the presence of ferric ions in acid medium has allowed the presence of a complex to be identified, the formula of the FeCip2+ itself to be established, by Job’s continuous variations method, and the dissociation constant K = (8.77 ± 0.92) × 10-10 (pK=9.06±0.05) to be calculated by two different methods: titration method and Bjerrum’s method of corresponding solutions The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to spectrophotometry ciprofloxacin solution ferric chloride, Pharmaceutical Analysis: Natural Drug Materials and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 16, 1986, Orjales Venero, Aurelio; Toledo Avello, Antonio published a patent.Synthetic Route of 59695-29-3 The title of the patent was Process for the preparation of amide derivatives of 4-amino-1,2,3,4,4a,9b-hexahydro-8,9b-dimethyldibenzofuran-3-one. And the patent contained the following:

The title amides I (R = alkyl; n = 1-4), known to be useful as analgesics and antitussives, are prepared by amidation of the title amine (II) with the corresponding (alkylpiperazinyl)alkanoic acids III in an anhydrous organic solvent and in the presence of a dehydrating agent. Thus, a solution of II.HCl in DMF was neutralized with K2CO3, filtered, and added to a solution of III.2HCl (R = Me, n = 2) and DCC in DMF, followed by workup and acidification, to give 50% I.2HCl (R = Me, n = 2). The experimental process involved the reaction of 3-(4-Methylpiperazin-1-yl)propanoic acid dihydrochloride(cas: 59695-29-3).Synthetic Route of 59695-29-3

The Article related to dibenzofuranone piperazinylalkanoylamino preparation analgesic antitussive, piperazinylalkanoylaminodibenzofuranone preparation analgesic antitussive, Heterocyclic Compounds (One Hetero Atom): Furans and other aspects.Synthetic Route of 59695-29-3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 11, 1998, De Laszlo, Stephen E.; Liverton, Nigel J.; Ponticello, Gerald S.; Selnick, Harold G.; Mantlo, Nathan B. published a patent.Electric Literature of 890092-19-0 The title of the patent was Preparation of arylpyrroles as cytokine inhibitors. And the patent contained the following:

Title compounds [I; R1 = H, alkyl, heterocyclyl, aryl, etc.; R2 = alk(en)yl, alkynyl, heterocyclyl, etc.; R3 = H, halo, alkyl, heterocyclyl, etc.; R4 = (un)substituted heteroaryl; R5 = ZR; R = 1-3 of halo, alkyl, acyl, (hetero)aryl, etc.; Z = (hetero)arylene] were prepared Thus, R5COCH2R4 (R4 = 4-pyridyl, R5 = 4-FC6H4) was α-alkylated by ClCH2COR2 (R2 = 1-benzyloxycarbonyl-4-piperidinyl)(preparation each given) and the product cyclocondensed with NH4Ac to give, after reduction, I (R1 = R3 = H, R2 = 1-methyl-4-piperidinyl, R4 = 4-pyridyl, R5 = 4-FC6H4). Data for biol. activity of I were given. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Electric Literature of 890092-19-0

The Article related to arylpyrrole preparation cytokine inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Electric Literature of 890092-19-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 27, 2022, Lee, Song Hee; Ryu, Je Ho; Ahn, Jung Min; Choi, Yu Ri; Lee, Ho Hyun; Jang, Mi Young; Woo, Yae Jin; Kim, Hanwool; Kim, Ji Young; Park, Ji Youn published a patent.Related Products of 1211568-27-2 The title of the patent was Amide compound for androgen receptor degradation, and pharmaceutical use thereof. And the patent contained the following:

The present invention provides a compound I [R1 = H, alkyl, halogen, etc.; R2 = H, alkyl, halogen, etc.; X1, X3, X4 and X5 = independently CH or N; X2 = CR3 or N; R3 = H, alkyl, halogen, etc.; n = 0, 1, or 2; m = 0 or 1; L = -(CH2)q1-A1-(CH2)q2-B1-(CH2)q3-A2-(CH2)q4-B2-(CH2)q5-A3-(CH2)q6-B3-; A1, A2 and A3 = independently direct bond, -O-, -N(R4)-, etc.; R4 = H, alkyl or haloalkyl; B1, B2 and B3 = independently direct bond, cycloalkyl, heterocycle, etc.; q1-q6 = independently 0-6; E = Q1 or Q2; X6, X7, X8 and X9 = independently CH or N; Y = -C(R6)2-, -C(O)-, -C(R6)2-C(R6′)2-, etc.; Z = direct bond, -C(R6)2-, -O-, etc.; R5 and R5′ = independently H, alkyl, halogen, etc.; R6 and R6′ = independently H, alkyl, halogen, etc.] of a specific chem. structure, having androgen receptor (AR) degradation activity, or a pharmaceutically acceptable salt thereof. The present invention also provides a composition containing the compound or a pharmaceutically acceptable salt thereof. According to present invention, provided is a pharmaceutical use of the compound, the salt thereof, and the composition containing same for treating or preventing AR-related diseases. According to the present invention, further provided is a method for treating or preventing AR-related diseases, the method comprising administering, to a subject in need of treatment, an effective amount of the compound, the salt thereof, or the composition containing same. For example, compound II (preparation given) was coupled with compound III (preparation given) to provide compound IV. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).Related Products of 1211568-27-2

The Article related to amide compound preparation androgen receptor degradation activity, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Related Products of 1211568-27-2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics